Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Manufacturing method of drug vessel support with antibody immobilized on surface of support

A vascular stent and surface fixation technology, applied in the field of vascular stents, can solve the problems of promoting endothelial repair, no antibody binding active site, less antibody binding, etc., and achieve the effect of promoting endothelial cell repair and excellent treatment of restenosis.

Inactive Publication Date: 2011-04-20
INST OF BIOMEDICAL ENG CHINESE ACAD OF MEDICAL SCI
View PDF5 Cites 11 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The disadvantage of the vascular stent is that there are no abundant antibody binding active sites on the surface of the stent, and the binding of the endothelial progenitor cells to capture antibodies is limited to a simple physical adsorption method. Compared with the chemical coupling method of the present invention, the amount of antibody binding Less and poor binding stability
The disadvantage of this vascular stent is that the drugs contained in the stent are limited to drugs that inhibit the proliferation of smooth muscle cells, cannot selectively adsorb endothelial progenitor cells to promote endothelial repair, and cannot avoid the risk of stent thrombosis due to delayed endothelial repair

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Manufacturing method of drug vessel support with antibody immobilized on surface of support
  • Manufacturing method of drug vessel support with antibody immobilized on surface of support
  • Manufacturing method of drug vessel support with antibody immobilized on surface of support

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0067] In Example 1, the material of the stent body is: stainless steel material; the selected polyester polymer is: polylactide glycolide, the selected anti-smooth muscle cell proliferation drug is paclitaxel, and the selected endothelial progenitor cells The capture antibody is CD133 antibody; the preparation process of a drug vascular stent with CD133 antibody and paclitaxel immobilized on the surface of the stent body is as follows:

[0068] Step A-1, preparation of polylactide glycolide with carboxyl functional groups:

[0069] According to the ratio of 1:15 in mass ratio, the polylactide glycolide is dissolved in the polymerization sealed tube equipped with dichloromethane, maleic anhydride and dibenzoyl peroxide are added to the above solution, and the The mass ratio of polylactide glycolide to maleic anhydride and dibenzoyl peroxide is 100:30:5, and the solvent is removed with a vacuum pump, and the vacuum is replaced with nitrogen for 3 times, and the tube is sealed a...

Embodiment 2

[0079] In Example 2, the material of the stent body is: stainless steel material; the selected polyester polymer is: polylactide, the selected anti-smooth muscle cell proliferation drug is rapamycin, and the selected endothelial progenitor cells The capture antibody is CD34 antibody; the preparation process of a drug vascular stent with CD34 antibody and rapamycin immobilized on the surface of the stent body is as follows:

[0080] Step A-1, preparation of polylactide with carboxyl functional groups:

[0081] According to the ratio of 1:40 in mass ratio, the polylactide is dissolved in the polymerization sealed tube containing dichloromethane, maleic anhydride and dibenzoyl peroxide are added to the above solution, and the polylactide The mass ratio with maleic anhydride and dibenzoyl peroxide is 100:40:8, remove the solvent with a vacuum pump, and replace it with nitrogen for 4 times, seal the tube at a vacuum of 80 Pa, and react for 48 hours at 100°C. Cool to room temperatu...

Embodiment 3

[0091] In Example 3, the material of the stent body is: stainless steel; the selected polyester polymer is: polyethylene glycol polylactide block polymer, and the selected anti-smooth muscle cell proliferation drug is dexamethasone Methasone, the selected endothelial progenitor cell capture antibody is CD31 antibody; the preparation process of a drug vascular stent with CD31 antibody and dexamethasone fixed on the surface of the stent body is as follows:

[0092] Step A-1, preparation of polyethylene glycol-polylactide block polymers with carboxyl functional groups:

[0093] According to the mass ratio of 1:5-40, the polyethylene glycol polylactide block polymer is dissolved in the polymerization sealed tube containing dichloromethane, and maleic anhydride and peroxide are added to the above solution. Dibenzoyl, the mass ratio of the polyethylene glycol polylactide block polymer to maleic anhydride and dibenzoyl peroxide is 100:5:1, and the solvent is removed with a vacuum pum...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a manufacturing method of a drug vessel support with antibody immobilized on the surface of the support. The manufacturing method comprises the following steps: 1) preparing polyester high polymer with carboxyl functional groups by using a synthesis or hydrolysis mode; 2) coating drug loading polyester high polymer on the surface of the support; and 3) immobilizing the antibody with the function of capturing endothelial progenitor cells on the surface of the support body by using a chemical coupling mode. In respect of the drug vessel support with antibody immobilized on the surface of the support, polyester high polymer with carboxyl functional groups is taken as the support drug loading coating to obtain the drug support the surface of which is subject to carboxylation, so that the surface of the support has both biocompatible compatibility and biological activity, and the carboxyl functionalized surface of the support provides abundant binding sites for loading effective dosage of antibody in the next step. Meanwhile, the support has a drug carrying function and an endothelial cell capturing function, thereby playing excellent roles in treating restenosis and promoting endothelial cell repairing.

Description

technical field [0001] The invention relates to a vascular stent, in particular to a drug vascular stent with antibodies fixed on its surface and a preparation method thereof. Background technique [0002] Coronary atherosclerotic heart disease (CHD) is one of the major diseases that endanger human health. Coronary artery intervention (PCI) has become an important method with definite curative effect in the clinical treatment of CHD. However, in the treatment of coronary artery stent implantation, there is the problem of postoperative vascular restenosis. About 15-30% of all stent placement cases in the world have restenosis, which seriously limits the long-term effect of treatment. So far, it is still a clinical problem. Problems that need to be solved urgently. In recent years, the emergence of drug-eluting stents has become a new milestone in the history of PCI development. The widespread application of drug-eluting stents has greatly reduced the occurrence of in-stent ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61L31/10A61L31/16
Inventor 马桂蕾宋存先孙洪范
Owner INST OF BIOMEDICAL ENG CHINESE ACAD OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com